Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Profiles and Treatment Patterns Among ALK-positive NSCLC Patients Treated With Alectinib

NCT04351334 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04351334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04351334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Profiles and Treatment Patterns Among ALK-positive NSCLC Patients Treated With Alectinib
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
March 1, 2020
Completion date
November 1, 2022
Enrollment
161 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma